Tenecteplase Boosts Late-Window Reperfusion but Not 90-Day Function
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Low
Cheng X, Hong L, Lin L, et al.
Jan 2, 2025 · Published in: Stroke
Tenecteplase enhances late-window stroke reperfusion without added hemorrhage risk.
Blood Biomarker Guideline Sets Accuracy Thresholds for Alzheimer's Workup
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Jan 1, 2025 · Published in: Alzheimer's & Dementia
This Alzheimer's Association guideline gives pharmacists concrete sensitivity and specificity thresholds for judging whether a plasma Alzheimer's test is fit for triaging or confirmatory use in specialty memory care.
EASL-EASD-EASO Guidelines Redefine MASLD Care With Resmetirom Entry
Guideline Gastroenterology / Hepatology Practice-changing Grade: Moderate
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)
Sep 1, 2024 · Published in: Journal of Hepatology
New guidelines transform MASLD management with non-invasive testing and targeted therapies.
Fixed Low-Dose Oral Esketamine Fails in Treatment-Resistant Depression
Analysis Psychiatry / Psychopharmacology Inconclusive Grade: Low
Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, et al.
Sep 1, 2024 · Published in: Molecular Psychiatry
Oral esketamine may be effective only at higher doses for resistant depression.
Survodutide Improves MASH Histology Across Doses in Phase 2
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Moderate
Sanyal AJ, Bedossa P, Fraessdorf M, et al.
Jul 25, 2024 · Published in: The New England Journal of Medicine
Survodutide shows promise in treating MASH without worsening fibrosis.
Tirzepatide Resolves MASH but Fibrosis Benefit Remains Unproven
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Moderate
Loomba R, Hartman ML, Lawitz EJ, et al.
Jul 25, 2024 · Published in: The New England Journal of Medicine
Tirzepatide offers potential new hope for MASH management.
Finerenone Cuts Albuminuria in Type 1 Diabetes with CKD
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Moderate
Perkovic V, Tuttle KR, Rossing P, et al.
May 24, 2024 · Published in: New England Journal of Medicine
Semaglutide slashes kidney and heart risks in diabetes with kidney disease.
Clinical pharmacy performance indicators skew to process, lack validation
Analysis Clinical Pharmacy Practice Hypothesis-generating Grade: Low
Magedanz L, Silva HL, Galato D, et al.
Apr 3, 2024 · Published in: International Journal of Clinical Pharmacy
Hospital pharmacy KPIs lack validation and benchmark standards.
KDIGO 2024 Chronic Kidney Disease Guideline: Precision CKD Care for Pharmacists
Guideline Chronic Kidney Disease Practice-changing Grade: Moderate
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
Apr 1, 2024 · Published in: Kidney Int
The 2024 KDIGO guideline for CKD introduces new recommendations for screening, diagnosis, risk stratification, pharmacologic intervention, and bone-mineral disorder, with significant implications for pharmacist monitoring roles.
TIMELESS: Late-Window Tenecteplase Fails to Improve Stroke Outcomes
Analysis Neurology / Neuropharmacology Confirmatory Grade: High
Albers GW, Jumaa M, Purdon B, et al.
Feb 22, 2024 · Published in: New England Journal of Medicine
Tenecteplase fails to outperform placebo in delayed stroke treatment.
Semaglutide Cuts Cardiovascular Events in Obesity Without Diabetes
Analysis Endocrinology / Diabetes / Obesity Practice-changing Grade: High
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
Nov 11, 2023 · Published in: New England Journal of Medicine
Semaglutide cuts heart risks in obesity without diabetes.
Adagrasib Shows Tumor-Agnostic Activity in Rare KRAS G12C Solid Tumors
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Bekaii-Saab TS, Yaeger R, Spira AI, et al.
Sep 1, 2023 · Published in: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Adagrasib shows promise in rare KRASG12C-mutated tumors.
Semaglutide Cuts Symptoms and Weight in Obesity-Related HFpEF
Analysis Endocrinology / Diabetes / Obesity Practice-changing Grade: High
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.
Aug 25, 2023 · Published in: New England Journal of Medicine
Semaglutide enhances function and weight loss in obese heart failure patients.
Sotorasib Shows Modest Activity in KRAS G12C Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Strickler JH, Satake H, George TJ, et al.
Jan 5, 2023 · Published in: The New England Journal of Medicine
Sotorasib offers hope for KRAS p.G12C-mutated pancreatic cancer.
CPIC 2022 Update: CYP2C19 Genotype and Clopidogrel Therapy
Guideline Pharmacogenomics Practice-changing Grade: Moderate
Lee CR, Luzum JA, Sangkuhl K, et al.
Nov 1, 2022 · Published in: Clin Pharmacol Ther
The strength of recommendation to avoid clopidogrel in CYP2C19 intermediate metabolizers is elevated to strong, and genotype-guided antiplatelet therapy now formally extends to neurovascular indications.